Omega-3 fatty acids has been studied in 899 papers since 1987: 298 trials and 109 observational studies in people, 30 in animals, 445 reviews; 218 in the past year. The newest story, Nov 14, 2026: “Omega-3s did not significantly cut major cardiovascular events”.
A human trial reports lower mortality with omega-3 fatty acids; another reports lower aging-clock measures, but trials show no clear effect on frailty or cognition. Independent labs reproduce triglyceride reductions in humans and inflammation reductions in mice. Developers sponsor most trials; 10 concern aging, and across all uses, two ended over a year ago without posted results or citing papers.
645 findings in 326 papers from 1987 to 2026, 32 of them since April 2026
Independent labs found the same change in mice and people. 181 independent labs in 37 countries; 22 trials, 11 about aging, 3 with no results posted.
“the n-3 FA supplement did not significantly reduce the primary endpoint of major CVD events”
Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
181 independent labs in 37 countries
73 findings against
22 trials, 11 about aging, 3 with no results posted
Omega-3 fatty acids decrease triglyceride in humans (added to statin therapy versus statin alone).
“Significant reduction of hepatic enzymes activity, systolic blood preasure, inflammatory markers and TAG levels were detected in both groups in comparison to the control group.”
Human trialadded to statin therapy versus statin alone2.52 g/day3 months
Journal of basic and clinical physiology and pharmacology·
Omega-3 fatty acids decrease triglyceride in humans (obesity).
“significantly decreased the concentrations of several inflammatory markers (SELE, MCP-1, sVCAM-1, sPECAM-1, and hsCRP), fasting triglycerides and insulin”
Human trialobesityplasma1.8g EPA+DHA per day3 monthsfemales
Omega-3 fatty acids decrease triglyceride in humans with caloric restriction.
“This effect was greater and more significant in subjects also supplemented with n-3 PUFA (CR + n-3 group) whose decrease in fasting TG concentration and TG AUC during OGTT was approximately 30% below baseline (P = 0.0003).”
International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition·
Omega-3 fatty acids decrease inflammation in humans (combined with resistance training).
“For CRP measurements, the group effect was p > 0.055, the effect of the time factor was p < 0.002, and the effect of the group × time interaction was p > 0.122.”
Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30
Omega-3 fatty acids decrease inflammation in combination with vibration and resistance exercise.
“There was a trend, although non-significant, towards decreased IL-6 and IL-10 concentrations in the high-protein, omega-3-enriched group compared to control.”
Human trialin combination with vibration and resistance exerciseeight weeksn = 61
Omega-3 fatty acids decrease inflammation in humans (obesity).
“n-3 PUFA supplementation, in contrast to placebo, significantly decreased the concentrations of several inflammatory markers (SELE, MCP-1, sVCAM-1, sPECAM-1, and hsCRP)”
Human trialobesityplasma1.8g EPA+DHA per day3 monthsfemales
Omega-3 fatty acids improve cognitive function in humans (Δ ≈ +4.2 points).
“Both groups showed statistically significant improvements in global cognitive scores on the Addenbrooke’s Cognitive Examination (ACE) (Δ ≈ +4.2 points)”
Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria·
Omega-3 fatty acids showed no clear effect on cognitive function in humans (individuals with raised baseline p-tau181, 12.4 pg/mL cutoff) (0.03 (95% CI -0.30 to 0.36)).
“mean difference [95% CI] in this subgroup in 3-year decline on the composite cognitive score between the control group and the multidomain + omega-3 group, the omega-3 group, and the multidomain intervention group, was, respectively: 0·13 [-0·21 to 0·47], 0·03 [-0·30 to 0·36]”
Human trialindividuals with raised baseline p-tau181, 12.4 pg/mL cutoff3-yearn = 527
Omega-3 fatty acids showed no clear effect on cognitive function in humans (healthy community-dwelling) (mean difference -0.01 standard units (95% CI: -0.02, 0.003; P = .15)).
“We observed no significant effect of n-3 supplementation: the mean difference in annual rate of cognitive change for the n-3 versus placebo group was -0.01 standard units”
Human trialhealthy community-dwelling1 g/day2 to 3 yearsn = 3,424
Omega-3 fatty acids impair cognitive function in humans (high CAIDE score (i.e., ≥6)) (mean±SE = - 1.01±0.46).
“There was significant less improvement (mean±SE = - 1.01±0.46) in the FCSRT free recall test in the n-3 PUFA intervention group compared to the placebo at 36 months.”
Human trialhigh CAIDE score (i.e., ≥6)36 monthsn = 1,293
Omega-3 fatty acids improve cognitive function in older adults.
“Omega-3 supplementation has also been associated with improvements in inflammatory markers, cardiometabolic risk, cognitive function, and physical capacity in older adults.”
Omega-3 fatty acids improve cognitive function in healthy older adults and patients with mild cognitive impairment.
“supplementation, especially with DHA and EPA, acts through anti-inflammatory and antioxidant mechanisms, notably benefiting healthy older adults and patients with mild cognitive impairment.”
Reviewin healthy older adults and patients with mild cognitive impairment
Omega-3 fatty acids improve physical function in humans (combined with resistance training).
“For BP measurements, the group effect was p > 0.061, the effect of the time factor was p < 0.003, and the effect of the group × time interaction was p > 0.099.”
Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30
The Journal of clinical endocrinology and metabolism·
Omega-3 fatty acids showed no clear effect on physical function in humans.
“treatment with vitamin D3, omega-3 fatty acids, or a strength training exercise program didn't result in clinically significant changes in blood pressure, nonvertebral fractures, physical performance, infection rates, or cognitive function”
Omega-3 fatty acids showed no clear effect on muscle mass in humans (perioperative period of bariatric surgery) (p = 0.300).
“Between baseline and 105 days, muscle mass decreased significantly in both groups (-3.1 ± 0.3 kg; -2.2 ± 0.5 kg; both p < 0.001), without interaction between groups (p = 0.300).”
Human trialperioperative period of bariatric surgery2000 mg/day of EPA + DHA90 daysn = 58
Omega-3 fatty acids increase muscle mass in humans.
“There was a main effect of time with RET (P < 0.01 (Interaction: P = 0.69)), yet only the n-3 PUFA group significantly increased TFFM in the trained leg (3961 ± 151 g (P < 0.05, MD = +187, 95% CI = [20, 355], d = 0.91)), with no change in PLA (3561 ± 170 g (P = 0.08, MD = +154, 95% CI = [−13, 322], d = 0.55)) ( A”
Omega-3 fatty acids increase muscle mass in humans with unilateral resistance exercise training (3774 ± 158 g to 3961 ± 151 g (P < 0.05) vs. 3406 ± 201 g to 3561 ± 170 PLA).
“Only the n-3 PUFA group increased TFFM (3774 ± 158 g to 3961 ± 151 g n-3 PUFA (P < 0.05) vs. 3406 ± 201 g to 3561 ± 170 PLA)”
Human trialwith unilateral resistance exercise trainingthigh3680 mg/day6 weeksfemalesn = 16
Omega-3 fatty acids showed no clear effect on muscle mass in humans (decreased muscle mass) (0.00 ± 0.30 kg/m2 in LMM-PUFA, 0.00 ± 0.22 kg/m2 in rLMM-PUFA).
“No statistically significant differences were observed either in muscle mass or in the hand grip and TUG in any group.”
Human trialdecreased muscle mass1.3 g PUFA and 10 mg vitamin E daily12 weeksn = 53
Omega-3 fatty acids showed no clear effect on muscle strength in humans (non-demented older adults) (between-group difference -0.05388 (-0.6800 to 0.5723, p = 0.8660)).
“The between-group differences compared with placebo were -0.05388 (-0.6800 to 0.5723; Standard Error, SE = 0.3192; p = 0.8660) for the ω3-PUFA group”
Human trialnon-demented older adults800 mg DHA and 225 mg EPA daily3 yearsn = 1,679
Current opinion in clinical nutrition and metabolic care·
Omega-3 fatty acids improve muscle strength in healthy and clinical older adult populations.
“Systematic reviews and meta-analyses of randomized controlled trials consistently report small, but clinically-relevant, effects of LC n -3 PUFA ingestion on strength outcomes”
Reviewin healthy and clinical older adult populations
Current opinion in clinical nutrition and metabolic care·
Omega-3 fatty acids improve muscle strength in humans (SMD = 0.12 [95% CI: 0.006, 0.24], P = 0.04).
“it showed a very small albeit significant positive effect on muscle strength (SMD = 0.12 [95% CI: 0.006, 0.24], P = 0.04) in participants when compared with placebo.”
“Omega-3 supplementation did not affect IL-6 stress reactivity (interaction effect p=0.11), but it did lower overall IL-6 levels (main effect F(2, 226)=3.73, p=0.03).”
Omega-3 fatty acids decrease IL-6 in humans (-0.19 pg/ml).
“The following compounds showed a significant small to large effect in reducing IL-6 levels: probiotics (-0.68 pg/ml), ARBs (-0.37 pg/ml) and omega-3 (-0.19 pg/ml).”
Omega-3 fatty acids decrease IL-6 in humans (-14%).
“The estimated mean stimulated log-IL-6 value was 0.15 units lower in the supplemented group than the placebo group, corresponding to 14% decrease in the geometric mean of IL-6 (p=.04).”
Omega-3 fatty acids showed no clear effect on IL-6 in patients with digestive system cancer.
“variations in the IL-6 and CRP concentrations in patients with digestive system cancer did not differ between the supplementation groups and the controls”
Omega-3 fatty acids decrease mortality in humans (posterior HRs 0.91–0.92).
“Without skepticism into the priors, ranges of posterior HRs for total CVD, cardiovascular death and all-cause death were 0.95–0.96, 0.91–0.92 and 0.95–0.96, respectively.”
Human trialmedian of 5.3 years (range, 3.8 to 6.1)n = 25,871
Omega-3 fatty acids decrease mortality in humans (posterior HR 0.95-0.96).
“Without skepticism into the priors, posterior HRs were 0.95-0.96 in CVD, 0.91-0.92 in cardiovascular death, and 0.95-0.96 in all-cause death risks, respectively.”
Omega-3 fatty acids are linked with lower mortality in humans.
“SHAP analysis revealed that intake of magnesium and n-3 fatty acid were associated with reduced risk of both advanced CKM stages and all-cause mortality.”
Omega-3 fatty acids showed no clear effect on mortality in humans (acute myocardial infarction) (RR 1.06, 95% CI 0.90 to 1.27).
“Omega 3 fatty acids probably make little or no difference to all-cause mortality (4 studies 9141 patients RR 1.06 - CI95% 0.90 to 1.27, moderate certainty)”
Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (aHR = 1.00, 95% CI 0.64–1.56).
“Based on the main effects analysis, we did not find any statistically significant benefit of any of the three interventions with regard to the risk of MACE: omega-3 versus no omega-3 (adjusted hazard ratio (aHR) = 1.00, 95% CI 0.64–1.56), nor vitamin D3 versus no vitamin D3 (aHR = 1.37, 95% CI 0.88–2.14), SHEP versus control exercise (aHR = 1.18, 95% CI 0.76–1.84”
Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (reciprocal win ratio 0.90, 95% CI 0.78 to 1.04, p = 0.15).
“The total numbers of winners and losers were 5,000,010 and 4,510,845, respectively, in the n−3 fatty acid vs. placebo groups, resulting in slightly but not significantly reduced reciprocal win ratios (95% CI) of 0.90 (0.78 to 1.04; p = 0.15) in all participants.”
Human trialmedian follow-up period of 5.3 years (ranging from 3.8 to 6.1 years)n = 25,871
Omega-3 fatty acids protect against cardiovascular disease in humans.
“synthesize the clinical evidence supporting omega-3 supplementation in cardiovascular protection, neuroprotection, and the mitigation of autoimmune and metabolic dysregulation”
Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (general population unselected for elevated cardiovascular risk) (HR = 0.92 (95% confidence interval 0.80-1.06)).
“Compared with an olive oil placebo, the n-3 FA intervention did not significantly reduce the primary endpoint of major CVD events”
Reviewgeneral population unselected for elevated cardiovascular risk1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid1 g/daymedian of 5.3 yearsn = 25,871
“Evidence supporting that n-3 PUFAs might have beneficial effects on maintaining telomere length reinforce the salutary effects of these dietary fats.”
Omega-3 fatty acids increase omega-3 index in humans.
“For the second principal comparison, ω-3 supplementation compared with placebo, similar results were observed. Ω-3 supplementation resulted in significant increases in the O3I and erythrocyte concentrations of EPA and total n–3 PUFAs when compared with those in the placebo group (all FDR P < 0.05).”
Omega-3 fatty acids increase omega-3 index in humans (healthy adults with low-fish intake and O3I <6%) (+2.03% ± 0.88%).
“Consumption of 2 portions of fish/week and ω-3 supplementation resulted in a significant mean % increase in O3I of 2.27% ± 0.82% and 2.03% ± 0.88%, respectively.”
Human trialhealthy adults with low-fish intake and O3I <6%700 mg EPA+DHA supplement capsule daily8-wkn = 40
Omega-3 fatty acids increase omega-3 index in humans.
“The post intervention ω-3 index was significantly higher and AA/EPA significantly lower in the ω-3 PUFA compared to the placebo group (p < 0.01, p < 0.05, respectively).”
Omega-3 fatty acids increase omega-3 index in humans (compared to pre-supplementation levels) (p < 0.001).
“A significantly higher ω-3 index and lower AA/EPA ratio was observed after ω-3 PUFA compared to pre-supplementation levels (p < 0.001 and p < 0.001, respectively).”
Human trialcompared to pre-supplementation levels3 weeksn = 24
Omega-3 fatty acids showed no clear effect on autoimmune disease in humans (0.85, 0.67 to 1.08).
“For the omega 3 fatty acid group, confirmed autoimmune disease occurred in 130 participants in the treatment group and 148 in the placebo group (0.85, 0.67 to 1.08, P=0.19; ).”
Omega-3 fatty acids showed no clear effect on autoimmune disease in humans (HR 0.85, 95% CI 0.67 to 1.08).
“In the omega 3 fatty acids arm, 130 participants in the treatment group and 148 in the placebo group had a confirmed autoimmune disease (0.85, 0.67 to 1.08, P=0.19).”
Human trial1000 mg/daymedian of 5.3 yearsn = 25,871
Omega-3 fatty acids protect against autoimmune disease in humans.
“synthesize the clinical evidence supporting omega-3 supplementation in cardiovascular protection, neuroprotection, and the mitigation of autoimmune and metabolic dysregulation”
Omega-3 fatty acids decrease oxidative stress and ROS signaling in humans (combined with resistance training).
“For malondialdehyde measurements, the group effect was p > 0.210, the effect of the time factor was p < 0.005, and the effect of the group × time interaction was p > 0.091.”
Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30
Omega-3 fatty acids decrease oxidative stress and ROS signaling in preclinical models.
“Preclinical evidence demonstrates that omega-3 PUFAs attenuate oxidative stress and inflammatory signalling, partly through RAGE axis regulation and PPARγ activation.”
Studies link omega-3 fatty acids with 81 measures, most often myocardial infarction (7 studies), cardiovascular disease (6) and coronary artery disease (5).
Myocardial infarction
↓downin humans7HR 0.72–0.9
7 studies
Omega-3 fatty acids lower the risk of myocardial infarction in humans (primary prevention) (HR 0.72, 95% CI 0.59–0.90).
“did significantly reduce total myocardial infarction (MI; HR=0.72 [0.59-0.90])”
Human trialprimary prevention1 g/daymedian of 5.3 yearsn = 25,871
Omega-3 fatty acids lower the risk of myocardial infarction in humans.
“Effects of omega-3 FA supplementation on CHD and total MI were robust across the priors, with the posterior HR estimates varying from 0.88 – 0.93 and 0.82 – 0.90, respectively.”
Human trialmedian of 5.3 years (range, 3.8 to 6.1)n = 25,871
Omega-3 fatty acids lower the risk of myocardial infarction in humans (reciprocal win ratio 0.71, 95% CI 0.57 to 0.88, p = 0.002).
“However, we obtained significant reciprocal win ratios (95% CI) of 0.71 (0.57 to 0.88; p = 0.002) and 0.83 (0.71 to 0.96; p = 0.01), respectively, for the hierarchical composite outcomes of MI and CHD events, showing significant benefits of the n−3 fatty acid supplementation for these two outcomes.”
Human trialmedian follow-up period of 5.3 years (ranging from 3.8 to 6.1 years)n = 25,871
Omega-3 fatty acids lower the risk of myocardial infarction in humans (general population unselected for elevated cardiovascular risk) (HR = 0.72 (0.59-0.90)).
“did significantly reduce total MI [HR = 0.72 (0.59-0.90)]”
Reviewgeneral population unselected for elevated cardiovascular risk1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid1 g/daymedian of 5.3 yearsn = 25,871
Omega-3 fatty acids are associated with cardiovascular disease in humans.
“Age-standardized death and DALYs rates for CVD attributable to low seafood n-3 polyunsaturated fatty acids (PUFAs) and high trans fatty acids declined”
Omega-3 fatty acids lower the risk of cardiovascular disease in humans.
“Evidence from clinical and epidemiological studies supports the health benefits of Omega-3 fortification, including reduced risk of cardiovascular diseases”
Omega-3 fatty acids lower the risk of coronary artery disease in humans (top tertile of the expected benefit) (1.21% absolute risk reduction vs 0.47% average).
“there was 1.21% absolute CHD risk reduction in the top tertile of the expected benefit, compared with the average effect of 0.47% risk reduction.”
Human trialtop tertile of the expected benefit5-yearn = 25,871
Omega-3 fatty acids lower the risk of coronary artery disease in humans.
“According to primary informed priors, probabilities of omega-3 FA being effective versus placebo (i.e. posterior HR < 1) were 99.7% for CHD, 99.6% for total MI, 98.4% for CVD, 98.8% for all-cause death, 99.8% for cardiovascular death, and 33.7% for stroke, respectively.”
Human trial1 g per daymedian of 5.3 years (range, 3.8 to 6.1)n = 25,871
Omega-3 fatty acids lower the risk of coronary artery disease in humans.
“omega-3 supplementation significantly decreased the risks of coronary heart disease and myocardial infarction only, in the comparison with the control group”
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·
Omega-3 fatty acids are associated with cognitive function in humans (beta 0.53, 95% CI: 0.33-0.72, P < 0.0001).
“the beta coefficients for the CERAD Word Learning test, Animal Fluency Test, and Digit Symbol Substitution Test were 0.53 (95% CI: 0.33-0.72, P < 0.0001)”
Omega-3 fatty acids are associated with cognitive function in humans (P for non-linearity = 0.01, P for dose-response = 0.005).
“Levels of episodic memory decreased with the increase in omega-3 dose and then appeared to increase with an upward curve (P for non-linearity = 0.01, P for dose-response = 0.005).”
Omega-3 fatty acids are associated with Alzheimer's disease in humans (Adjusted for potential confounders) (OR 0.36, 95% CI 0.18–0.74; 64% lower odds).
“individuals in the third tertile of total dietary omega-3 fatty acids had 64 percent lower chance of Alzheimer's disease”
HumansAdjusted for potential confoundersthird tertile of total dietary omega-3 fatty acidsn = 301
Omega-3 fatty acids are associated with Alzheimer's disease in humans (Highest versus lowest quintile of total omega-3 status) (Q5 vs. Q1: HR 0.87, 95% CI 0.76–1.00).
“the total omega-3 status was inversely related to the risk of Alzheimer's”
HumansHighest versus lowest quintile of total omega-3 statusn = 267,312
Omega-3 fatty acids are associated with Alzheimer's disease in humans.
“The available data suggests that food items rich in antioxidants, omega-3 fatty acids, and B vitamins are associated with a lower risk of developing Alzheimer's disease.”
Omega-3 fatty acids lower the risk of Alzheimer's disease in humans (epidemiology cohorts).
“Epidemiology cohorts reveal associations between levels or intake of omega-3 polyunsaturated fatty acids (n-3 PUFA) and a lower risk of Alzheimer's disease (AD).”
Omega-3 fatty acids are linked with a lower risk of age-related macular degeneration in humans (HR 0.80, 95% CI 0.72-0.95).
“Higher plasma levels (in millimoles per liter) of omega-3 (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.72-0.95; P = 0.006) and DHA (HR, 0.65; 95% CI, 0.44-0.96; P = 0.029) were associated with lower risk of receiving an AMD diagnosis.”
Omega-3 fatty acids are linked with a lower risk of age-related macular degeneration in humans (early AMD) (RR 0.86, 95% CI 0.77-0.96).
“Higher dietary intakes of omega-3 PUFA was significantly associated with 14% (relative risk [RR]: 0.86, 95% confidence interval [CI]: 0.77, 0.96) and 29% (RR: 0.71, 95% CI: 0.55, 0.91) lower risk of early and late AMD, respectively.”
Omega-3 fatty acids lower the risk of age-related macular degeneration in humans (ES 0.51, 95% CI 0.34-0.75, p = 0.01).
“people with high dietary long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) have a lower risk of progression to advanced age-related macular degeneration (AMD) (effect size, ES: 0.51, 95 % CI [0.34, 0.75]”
Omega-3 fatty acids raise the risk of atrial fibrillation.
“High-dose ω-3 formulations, regardless of EPA monotherapy or EPA/DHA combination, carry a dose-dependent atrial fibrillation risk that warrants age-stratified assessment.”
ReviewEPA monotherapy or EPA/DHA combinationhigh-dose
Omega-3 fatty acids lower the risk of dementia in humans (observational studies).
“Observational studies generally associate higher dietary intake or circulating omega-3 status with better cognitive performance and a lower risk of cognitive decline and dementia.”
Omega-3 fatty acids are linked with a lower risk of mortality in humans (highest versus lowest intake quartile) (HR 0.75, 95% CI 0.61-0.92).
“Participants in the highest versus lowest intake quartile had 48% lower odds of severe CKM stage (OR, 0.52 [95% CI, 0.46-0.60]) and 25% lower mortality (HR, 0.75 [95% CI, 0.61-0.92]).”
Omega-3 fatty acids are associated with functional connectivity in humans (dependent on cognitive decline status).
“an effect of omega-3 fatty acid supplementation dependent on cognitive decline status was underlined for frontoparietal, salience, visual and sensorimotor networks FC.”
Human trialdependent on cognitive decline status36 monthsn = 100
Omega-3 fatty acids are associated with trail-making test A score in humans (baseline plasma homocysteine <= 16.8 umol/L) (Estimate: -1.3, 95% CI: -2.3; -0.3, p=0.01).
“We found a significant association between TMT-A and red blood cell n-3 PUFA levels in participants with Hcy values ≤16.8 μMol/L after adjustments at baseline (Estimate: -1.3, 95% CI: -2.3; -0.3, p=0.01).”
Human trialbaseline plasma homocysteine <= 16.8 umol/L
National Heart, Lung, and Blood Institute$2.1MNational Institute of Diabetes and Digestive and Kidney Diseases$1.3MJapan Society for the Promotion of Science¥8.8M
Animal studies report lifespan extension in mice but shortening in rats. Independent labs report reduced triglycerides and inflammation and improved cognition in humans, alongside null inflammation and cognition results; a human trial reports lower epigenetic aging measures but another reports no effect on frailty. Two registered trials concern aging; most trials across uses have company sponsors, and papers declare company ties.
A human observational study links higher omega-3 intake to lower mortality; independent labs report lower human inflammation and triglycerides. Lifespan increases in tau-transgenic mice contrast with decreases in rats; some human inflammation studies report no effect. Two findings have company-affiliated authors, and three papers declare company ties.
Summary rewritten as its findings changed.
As it read before
Reviews reach conflicting conclusions on cardiovascular health, describing lower coronary heart disease risk alongside an increased risk of atrial fibrillation with high-dose formulations in high-risk populations, whereas another review reports no effect on human cardiovascular disease.
Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.